{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T17:32:11Z","timestamp":1649093531791},"reference-count":37,"publisher":"Hogrefe Publishing Group","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Praxis"],"published-print":{"date-parts":[[2019,4]]},"abstract":" Zusammenfassung. Aktinische Keratosen (AK) sind durch chronische UVB-Sch\u00e4digung verursachte Hautver\u00e4nderungen, die durch gesteigerte Verhornung und Dysplasie der Hautzellen gekennzeichnet sind. AK k\u00f6nnen in ein Plattenepithelkarzinom \u00fcbergehen. Die Pr\u00e4valenz dieser an Sonnenlicht-exponierten Hautstellen auftretenden Erkrankung steigt mit zunehmendem Alter. Die Diagnose ist h\u00e4ufig eine Blickdiagnose. In Rezidiv- oder Zweifelsf\u00e4llen sollte eine histologische Sicherung erfolgen. Therapeutisch kommen verschiedene Behandlungsm\u00f6glichkeiten zur Anwendung, von ablativen bis topisch-medikament\u00f6sen Verfahren. Die Pr\u00e4vention hat einen hohen Stellenwert. Dieser Artikel will \u00fcber das Krankheitsbild informieren, Hilfestellung bei der Erkennung bieten und therapeutische M\u00f6glichkeiten aufzeigen. <\/jats:p>","DOI":"10.1024\/1661-8157\/a003231","type":"journal-article","created":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T03:00:21Z","timestamp":1556679621000},"page":"381-388","source":"Crossref","is-referenced-by-count":0,"title":["CME: UpDate Aktinische Keratosen"],"prefix":"10.1024","volume":"108","author":[{"given":"Susanne","family":"Angehrn","sequence":"first","affiliation":[{"name":"Hausarztpraxis zur Rehburg, St. Gallen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Tschernitz","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Dermatologie Kantonsspital St. Gallen"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"101","reference":[{"key":"c1","unstructured":"Hunger R, Reichmuth G: Aktinische Keratosen \u2013 Welches ist die beste Therapie? medicos 2011; 4: 2\u201310."},{"key":"c2","doi-asserted-by":"crossref","unstructured":"Trakatelli M, Ulrich C, del Marmol V, Euvrard S, Stockfleth E, Abeni D: Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol 2007; 156: 1\u20137.","DOI":"10.1111\/j.1365-2133.2007.07861.x"},{"key":"c3","doi-asserted-by":"crossref","unstructured":"Glogau RG: The risk of progression to invasive disease. J Am Acad Dermatol 2000; 42: 23\u201324.","DOI":"10.1067\/mjd.2000.103339"},{"key":"c4","doi-asserted-by":"crossref","unstructured":"Stockfleth E, Ulrich C, Meyer T, Christophers E: Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res 2002; 160: 251\u2013258.","DOI":"10.1007\/978-3-642-59410-6_30"},{"key":"c5","doi-asserted-by":"crossref","unstructured":"Harwood CA, Proby M: Human papillomaviruses and non-melanoma skin cancer. Curr Opin Infect Dis 2002; 15: 101\u2013114.","DOI":"10.1097\/00001432-200204000-00002"},{"key":"c6","unstructured":"Lucas R, McMichael T, Smith W, et al.: Environmental Burden of Disease Series, Solar Ultraviolet Radiation. Global Burden of Disease from Solar Ultraviolet Radiation. Geneva; World Health Organization, Public Health and the Environment: 2006; 13."},{"key":"c7","doi-asserted-by":"crossref","unstructured":"Anwar J, Wrone DA, Kimyai-Asadi A, Alam M: The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classi cation schemes. Clin Dermatol 2004; 22: 189\u2013196.","DOI":"10.1016\/j.clindermatol.2003.12.006"},{"key":"c8","unstructured":"AWMF-Leitlinie \u00abKryochirurgie in der Dermatologie\u00bb. https:\/\/www.awmf.org\/fileadmin\/user_upload\/Die_AWMF\/Service\/Gesamtarchiv\/QS-Empfehlung\/Kryochirurgie_in_der_Derma tologie.pdf; letzter Zugriff: 27.02.2019."},{"key":"c9","unstructured":"Hunger R, Reichmuth G: Aktinische Keratosen \u2013 Welches ist die beste Therapie? medicos 2011; 4: 2\u201310."},{"key":"c10","doi-asserted-by":"crossref","unstructured":"Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA: Imiquimod applied topically: a novel immune response modi er and new class of drug. Int J Immunopharmacol 1999; 21: 1\u201314.","DOI":"10.1016\/S0192-0561(98)00068-X"},{"key":"c11","doi-asserted-by":"crossref","unstructured":"Hemmi H, Kaisho T, Takeuchi O, et al.: Small anti-viral compounds activate immune cells via the TLR7 MyD88dependent signaling pathway. Nat Immunol 2002; 3: 196\u2013200.","DOI":"10.1038\/ni758"},{"key":"c12","doi-asserted-by":"crossref","unstructured":"Lebwohl M, Dinehart S, Whiting D, et al.: Imiquimod 5 % cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50: 714\u2013721.","DOI":"10.1016\/j.jaad.2003.12.010"},{"key":"c13","doi-asserted-by":"crossref","unstructured":"Harrison LI, Skinner SL, Marbury TC, et al.: Pharmacokinetics and safety of imiquimod 5 % cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch Dermatol Res 2004; 296: 6\u201311.","DOI":"10.1007\/s00403-004-0465-4"},{"key":"c14","doi-asserted-by":"crossref","unstructured":"Szeimies RM, Gerritsen MJ, Gupta G, et al.: Imiquimod 5 % cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004; 51: 547\u2013555.","DOI":"10.1016\/j.jaad.2004.02.022"},{"key":"c15","doi-asserted-by":"crossref","unstructured":"Kowalzick L, Ziegler H: Photoallergic contact dermatitis from topical diclofenac in Solaraze gel. Contact Dermatitis 2006; 54: 348\u2013349.","DOI":"10.1111\/j.0105-1873.2006.0645f.x"},{"key":"c16","doi-asserted-by":"crossref","unstructured":"Olsen EA, Abernethy ML, Kulp-Shorten C, et al.: A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol 1991; 24: 738\u2013743.","DOI":"10.1016\/0190-9622(91)70113-G"},{"key":"c17","doi-asserted-by":"crossref","unstructured":"Jackson S, Storey A: E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV -damage. Oncogene 2000; 19: 592\u2013598","DOI":"10.1038\/sj.onc.1203339"},{"key":"c18","doi-asserted-by":"crossref","unstructured":"Thompson SC, Jolley D, Marks R: Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993; 329: 1147\u20131151.","DOI":"10.1056\/NEJM199310143291602"},{"key":"c19","doi-asserted-by":"crossref","unstructured":"Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfeth E: A randomised study of topical 5 % imiquimod vs. topical 5-fuorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007; 157: 34\u201340.","DOI":"10.1111\/j.1365-2133.2007.08271.x"},{"key":"c20","doi-asserted-by":"crossref","unstructured":"Darlington S, Williams G, Neale R et al.: A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses. Arch Dermatol 2003; 139: 451\u2013455.","DOI":"10.1001\/archderm.139.4.451"},{"key":"c21","doi-asserted-by":"crossref","unstructured":"Naylor MF, Boyd A, Smith DW et al.: High sun protection factor sunscreens in the suppression of actinic neoplasma. Arch Dermatol 1995, 131: 170.","DOI":"10.1001\/archderm.1995.01690140054008"},{"key":"c22","doi-asserted-by":"crossref","unstructured":"Green A, Williams G, Neale R et al.: Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999; 354: 723\u2013729.","DOI":"10.1016\/S0140-6736(98)12168-2"},{"key":"c23","doi-asserted-by":"crossref","unstructured":"Ulrich C, J\u00fcrgensen JS, Degen A, et al.: Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009; 161: 78\u201384.","DOI":"10.1111\/j.1365-2133.2009.09453.x"},{"key":"c24","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Pr\u00e4vention von Hautkrebs, Langversion 1. 1, 2014, AWMF Registernummer: 032\/ 052OL, http:\/\/leitlinienprogramm-onkologie.de\/Leitlinien.7.0. html; letzter Zugriff: 26.02.2019."},{"key":"c25","doi-asserted-by":"crossref","unstructured":"Fecker LF, Stockfleth E, Nindl I, Ulrich C, Forschner T, Eberle J: The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-infammatory drugs (NSAIDs). Br J Dermatol 2007; 156: 25\u201333.","DOI":"10.1111\/j.1365-2133.2007.07856.x"},{"key":"c26","doi-asserted-by":"crossref","unstructured":"Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S: Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator activated receptor gamma in rheumatoid synovial cells. J Pharmacol Exp Ther 2002; 302: 18\u201325.","DOI":"10.1124\/jpet.302.1.18"},{"key":"c27","unstructured":"Altmeyers Enzyklop\u00e4die. Online-Portal \u00abAltmeyersenzyklop\u00e4die\u00bb Thema: Aktinische Keratosen, www.enzyklopaedie-dermatologie.de; letzter Zugriff: 26.02.2019."},{"key":"c28","doi-asserted-by":"crossref","unstructured":"Breitbart EW, Waldmann A, Nolte S, et al.: Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol 2012; 66: 201\u2013211.","DOI":"10.1016\/j.jaad.2010.11.016"},{"key":"c29","doi-asserted-by":"crossref","unstructured":"Waldmann A, Nolte S, Weinstock MA, et al.: Skin cancer screening participation and impact on melanoma incidence in Germany \u2013 an observational study on incidence trends in regions with and without population-based screening. Br J Cancer 2012; 106: 970\u2013974.","DOI":"10.1038\/bjc.2012.22"},{"key":"c30","doi-asserted-by":"crossref","unstructured":"Diepgen TL, Mahler V: The epidemiology of skin cancer. Br J Dermatol 2002; 146: 1\u20136.","DOI":"10.1046\/j.1365-2133.146.s61.2.x"},{"key":"c31","doi-asserted-by":"crossref","unstructured":"Rubel DM, Spelman L, Murrell DF, et al.: Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial. Br J Dermatol 2014; 171: 1164\u20131171.","DOI":"10.1111\/bjd.13138"},{"key":"c32","doi-asserted-by":"crossref","unstructured":"Lacour JP, Ulrich C, Gilaberte Y, et al.: Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator-blinded, controlled, phase III study throughout Europe. J Eur Acad Dermatol Venereol 2015; 29: 2342\u20132348.","DOI":"10.1111\/jdv.13228"},{"key":"c33","doi-asserted-by":"crossref","unstructured":"Zouboulis CC, R\u00f6hrs H: Cryosurgical treatment of actinic keratoses and evidence-based review. Hautarzt 2005; 56: 353\u2013358.","DOI":"10.1007\/s00105-004-0865-6"},{"key":"c34","unstructured":"Deutsche Dermatologische Gesellschaft\/ESFC Network: Leitlinie zur Behandlung der Aktinischen Keratosen. http:\/\/www.escf-network.eu\/fileadmin\/user_upload\/Files\/Leitlinie_AK_K5_Ds.pdf; letzter Zugriff: 26.02.2019."},{"key":"c35","doi-asserted-by":"crossref","unstructured":"Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L: IL-1beta-mediated up-regulation of HIF1alpha via an NF-kappa B\/COX-2 pathway identifies HIF-1 as a critical link between infammation and oncogenesis. FASEB J 2003; 17: 2115\u20132117.","DOI":"10.1096\/fj.03-0329fje"},{"key":"c36","doi-asserted-by":"crossref","unstructured":"Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B: Ingenol mebutate gel for actinic keratosis. NEJM 2012; 366: 1010\u20131019.","DOI":"10.1056\/NEJMoa1111170"},{"key":"c37","doi-asserted-by":"crossref","unstructured":"Shumack S, Stein Gold L, Melgaard A, Larsson T, Tyring SK: Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol 2013; 149: 666\u2013670.","DOI":"10.1001\/jamadermatol.2013.2766"}],"container-title":["Praxis"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/econtent.hogrefe.com\/doi\/pdf\/10.1024\/1661-8157\/a003231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:54:35Z","timestamp":1615942475000},"score":1,"resource":{"primary":{"URL":"https:\/\/econtent.hogrefe.com\/doi\/10.1024\/1661-8157\/a003231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1024\/1661-8157\/a003231"],"URL":"https:\/\/doi.org\/10.1024\/1661-8157\/a003231","relation":{},"ISSN":["1661-8157","1661-8165"],"issn-type":[{"value":"1661-8157","type":"print"},{"value":"1661-8165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}